226 related articles for article (PubMed ID: 15708542)
1. Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).
Atanasova SY; von Ahsen N; Toncheva DI; Dimitrov TG; Oellerich M; Armstrong VW
Clin Biochem; 2005 Mar; 38(3):223-8. PubMed ID: 15708542
[TBL] [Abstract][Full Text] [Related]
2. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy.
Toncheva DI; Von Ahsen N; Atanasova SY; Dimitrov TG; Armstrong VW; Oellerich M
J Nephrol; 2004; 17(3):384-9. PubMed ID: 15365958
[TBL] [Abstract][Full Text] [Related]
3. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Nikolov IG; Chernozemsky IN; Idle JR
IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
[TBL] [Abstract][Full Text] [Related]
4. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
5. MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls.
Atanasova S; von Ahsen N; Dimitrov T; Armstrong V; Oellerich M; Toncheva D
Nephron Exp Nephrol; 2004; 96(1):e7-13. PubMed ID: 14752243
[TBL] [Abstract][Full Text] [Related]
6. Balkan endemic nephropathy and genetic variants of glutathione S-transferases.
Andonova IE; Sarueva RB; Horvath AD; Simeonov VA; Dimitrov PS; Petropoulos EA; Ganev VS
J Nephrol; 2004; 17(3):390-8. PubMed ID: 15365959
[TBL] [Abstract][Full Text] [Related]
7. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
Ganoci L; Božina T; Mirošević Skvrce N; Lovrić M; Mas P; Božina N
Drug Metab Pers Ther; 2017 Mar; 32(1):11-21. PubMed ID: 28272018
[TBL] [Abstract][Full Text] [Related]
9. Common Polymorphisms in GSTA1, GSTM1 and GSTT1 Are Associated with Susceptibility to Urinary Bladder Cancer in Individuals from Balkan Endemic Nephropathy Areas of Serbia.
Matic M; Dragicevic B; Pekmezovic T; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Dragicevic D; Smiljic J; Simic T
Tohoku J Exp Med; 2016 Sep; 240(1):25-30. PubMed ID: 27568660
[TBL] [Abstract][Full Text] [Related]
10. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
11. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
12. Differential methylation pattern of xenobiotic metabolizing genes and susceptibility to Balkan endemic nephropathy, in a cohort of Romanian patients.
Ivan A; Lam D; Cristea MI; Telea A; Gruia AT; Oprean C; Margineanu F; Bojin FM; Saffery R; Paunescu V; Tatu CA
J Nephrol; 2020 Feb; 33(1):91-100. PubMed ID: 31222646
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
14. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
15. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
16. Association of a bitter taste receptor mutation with Balkan Endemic Nephropathy (BEN).
Wooding SP; Atanasova S; Gunn HC; Staneva R; Dimova I; Toncheva D
BMC Med Genet; 2012 Oct; 13():96. PubMed ID: 23050764
[TBL] [Abstract][Full Text] [Related]
17. Is increased susceptibility to Balkan endemic nephropathy in carriers of common GSTA1 (*A/*B) polymorphism linked with the catalytic role of GSTA1 in ochratoxin a biotransformation? Serbian case control study and in silico analysis.
Reljic Z; Zlatovic M; Savic-Radojevic A; Pekmezovic T; Djukanovic L; Matic M; Pljesa-Ercegovac M; Mimic-Oka J; Opsenica D; Simic T
Toxins (Basel); 2014 Aug; 6(8):2348-62. PubMed ID: 25111321
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
20. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
